Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2026 10:00 ET | Source: Curium

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...
July 02, 2025 09:00 ET | Source: Primo Biotechnology Co., Ltd.

Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy

TAIPEI, Taiwan, July 02, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series...
January 09, 2025 05:00 ET | Source: Primo Biotechnology Co., Ltd.

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Primo partners with SHINE to bring Ilumira to Asia-Pacific, advancing radioligand therapy and precision cancer care with exclusive rights in key markets.
January 08, 2025 21:00 ET | Source: Primo Biotechnology Co., Ltd.

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Primo partners with SHINE to bring Ilumira to Asia-Pacific, advancing radioligand therapy and precision cancer care with exclusive rights in key markets.
January 08, 2025 20:00 ET | Source: Primo Biotechnology Co., Ltd.

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Primo partners with SHINE to bring Ilumira to Asia-Pacific, advancing radioligand therapy and precision cancer care with exclusive rights in key markets.
January 08, 2025 10:00 ET | Source: Primo Biotechnology Co., Ltd.

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Primo partners with SHINE to bring Ilumira to Asia-Pacific, advancing radioligand therapy and precision cancer care with exclusive rights in key markets.